Clinical Trials
17 trialsNCT06712927 2026-05-18
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
Phase 2 Recruiting
NCT05012254 2026-05-05
NIVIPI-Brain
Fundación GECP
Phase 2 Active not recruiting
NCT04817254 2026-04-17
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05048212 2026-04-09
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT04511013 2025-09-11
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
Phase 2 Recruiting
NCT03890952 2025-07-24
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Rigshospitalet, Denmark
Phase 2 Completed
NCT03173950 2025-06-29
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02978404 2024-06-28
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Completed
NCT02621515 2024-05-06
CA209-322
University Medical Center Groningen
Phase 2 Terminated
NCT03925246 2024-04-02
REVOLUMAB
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT03728465 2021-02-03
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
University Hospital Tuebingen
Phase 2 Terminated